Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression

Transplantation

Volumn 95, Issue 4, 2013, Pages 566-572

  Narayanan, Mohanram ^a   Pankewycz, Oleh ^b   El Ghoroury, Mohamed ^c   Shihab, Fuad ^d   Wiland, Anne ^e   McCague, Kevin ^e   Chan, Laurence ^f  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b ERIE COUNTY MEDICAL CENTER   (United States)

^c St Clair Specialty Physicians   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

African American; EC MPS; MMF; Mycophenolic acid; Transplant

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AFRICAN AMERICAN; ARTICLE; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; FOLLOW UP; FRACTURE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; AGED; BIOPSY; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; ODDS RATIO; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84874617494     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318277438f     Document Type: Article

References (25)

1. Fan PY, Ashby VB, Fuller DS, et al. Access and outcomes among minority transplant patients, 1999-2008, with a focus on determinants of kidney graft survival. Am J Transplant 2010; 10: 1090.
2. Eckhoff DE, Young CJ, Gaston RS, et al. Racial disparities in renal allograft survival: a public health issue? J Am Coll Surg 2007; 204: 894.
3. Srinivas TR, Kaplan B, Schold JD, et al. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation 2005: 80: S211.
4. Lentine KL, Schnitzler MA, Xiao H, et al Racial variation in medical outcomes among living kidney donors. N Engl J Med 2010; 363: 724.
5. Press R, Carrasquillo O, Nickolas T, et al. Race/ethnicity, poverty status, and renal transplant outcomes. Transplantation 2005; 80: 917.
6. Meier-Kriesche HU, Ojo AO, Leichtman AB, et al. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am Soc Nephrol 2000; 11: 2366.
7. Omoloja A, Mitsnefes M, Talley L, et al. Racial differences in graft survival: a report from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Clin J Am Soc Nephrol 2007; 2: 524.
8. Ishitani M, Isaacs R, Norwood V, et al. Predictors of graft survival in pediatric living-related kidney transplant recipients. Transplantation 2000; 70: 288.
9. Isaacs RB, Nock SL, Spencer CE, et al. Racial disparities in renal transplant outcomes. Am J Kidney Dis 1999; 34: 706.
10. Butkus DE, Dottes AL, Meydrech EF, et al. Effect of poverty and other socioeconomic variables on renal allograft survival. Transplantation 2001; 72: 261.
11. Malat GE, Culkin C, Palya A, et al. African American kidney transplantation survival: the ability of immunosuppression to balance the inherent pre-and post-transplant risk factors. Drugs 2009; 69: 2045.
12. Dirks NL, Huth B, Yates CR, et al. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther 2004; 42: 701.
13. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994Y2004. Am J Transplant 2006; 6: 1111.
14. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65: 515.
15. Pescovitz MD, Guasch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant 2003; 3: 1581.
16. Tornatore KM, Sudchada P, Dole K, et al. Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients. J Clin Pharmacol 2011; 51: 1213.
17. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997; 64: 1277.
18. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200.
19. Tesi RJ, Deboisblanc M, Saul C, et al. An increased incidence of rejection episodes. One of the causes of worse kidney transplantation survival in black recipients. Arch Surg 1997; 132: 35.
20. Cecka JM. The UNOS Scientific Renal RegistryV2000. Clin Transpl 2000: 1.
21. Klein AS, Messersmith EE, Ratner LE, et al. Organ donation and utilization in the United States, 1999Y2008. Am J Transplant 2010; 10: 973.
22. Delanaye P, Mariat C, Maillard N, et al. Are creatinine-based equations accurate to estimate glomerular filtration rates in African American populations? Clin J Soc Nephrol 2011; 6: 906.
23. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604.
24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
25. Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005; 19: 199.